Combination therapy of G-CSF plus meloxicam can reduce the leukocytosis side effects, prevent postinjury RGCs apoptosis, preserve the visual function, halt the recruitment of macrophages to the optic nerve, and promote the M2 phenotype transition in macrophages. The gene discussed is CSF3; the disease is Increased total leukocyte count.